TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Taysha Gene Therapies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.94+0.32 (+8.84%)
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
91.9%
300M of 326M shares
Institutional holders
209
42 new, 22 sold out
Net institutional buying
34M
In Q2 2026
Insider trades, 12 months
0 buys · 12 sales
Net sold $6.66M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Kolchinsky | 32,886,242 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah | 27,662,481 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Paul B Manning | 25,601,111 | 9.80% | 13D (active) amendment | May 30, 2025 |
| RA Capital Healthcare Fund, L.P. | 25,345,988 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Avoro Capital Advisors LLC | 23,094,444 | 9.99% | 13G (passive) | Sep 30, 2024 |
| Roderick Wong | 20,689,084 | 7.00% | 13G (passive) amendment | Mar 31, 2026 |
| RTW Investments, LP | 20,673,307 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Ryan Wilder | 18,000,000 | 6.30% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 17,852,291 | 6.50% | 13G (passive) amendment | Dec 31, 2025 |
| Morgan Stanley | 16,244,339 | 5.10% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson | 15,627,822 | 6.20% | 13G (passive) amendment | Jun 30, 2025 |
| Vestal Point Capital, LP | 13,750,000 | 5.00% | 13G (passive) | Dec 31, 2025 |
| Goldman Sachs & Co. LLC | 12,748,968 | 5.10% | 13G (passive) | Jun 26, 2025 |
| Roderick Wong, M.D. | 12,368,334 | 5.90% | 13G (passive) amendment | Dec 31, 2024 |
| Octagon Capital Advisors LP | 10,450,000 | 5.10% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TSHA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 23,888,888 | 7.33% | $162.68M | +2,188,888 | 1.46% |
| Ra Capital Management, L.P. | 23,555,648 | 7.23% | $160.41M | – | 1.39% |
| Goldman Sachs Group Inc | 22,713,118 | 6.97% | $154.68M | +343,473 | 0.01% |
| BlackRock, Inc. | 20,691,927 | 6.35% | $140.91M | +2,326,319 | 0.00% |
| Vestal Point Capital, LP | 19,415,000 | 5.96% | $132.22M | +1,415,000 | 3.09% |
| Morgan Stanley | 16,487,479 | 5.06% | $112.28M | −1,477,892 | 0.01% |
| Rtw Investments, LP | 13,560,258 | 4.16% | $92.35M | −119,990 | 0.79% |
| FMR LLC | 13,336,413 | 4.09% | $90.82M | −984,842 | 0.00% |
| Vanguard Capital Management LLC | 12,478,595 | 3.83% | $84.98M | +2,247,093 | 0.00% |
| State Street Corp | 11,421,920 | 3.51% | $77.78M | +212,842 | 0.00% |
| Siren, L.L.C. | 9,846,579 | 3.02% | $67.06M | +1,016,666 | 1.36% |
| Octagon Capital Advisors LP | 9,693,244 | 2.97% | $66.01M | +833,333 | 5.93% |
| Geode Capital Management, LLC | 6,560,394 | 2.01% | $44.69M | +1,028,439 | 0.00% |
| Polar Capital Holdings Plc | 5,117,133 | 1.57% | $34.85M | −537,207 | 0.08% |
| Mpm Bioimpact LLC | 4,500,000 | 1.38% | $30.65M | New | 1.87% |
| D. E. Shaw & Co., Inc. | 4,398,652 | 1.35% | $29.95M | −28,649 | 0.01% |
| Baker Bros. Advisors LP | 4,004,756 | 1.23% | $27.27M | – | 0.14% |
| Wellington Management Group Llp | 3,975,605 | 1.22% | $27.07M | +3,349,244 | 0.00% |
| Healthcare Of Ontario Pension Plan Trust Fund | 3,885,501 | 1.19% | $26.46M | +1,002,200 | 0.04% |
| Casdin Capital, LLC | 3,250,000 | 1.00% | $22.13M | – | 1.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 209 | 300M | 91.9% | 42 / 99 | 41 / 22 | 48M | 14M |
| Q1 2026 | 191 | 266M | 81.6% | 35 / 69 | 49 / 35 | 39M | 28M |
| Q4 2025 | 195 | 269M | 82.6% | 64 / 62 | 46 / 22 | 42M | 35M |
| Q3 2025 | 155 | 265M | 81.3% | 28 / 61 | 35 / 20 | 35M | 28M |
| Q2 2025 | 150 | 258M | 79.3% | 44 / 48 | 34 / 20 | 96M | 5M |
| Q1 2025 | 127 | 167M | 51.2% | 22 / 39 | 31 / 25 | 22M | 22M |
| Q4 2024 | 131 | 167M | 51.4% | 28 / 45 | 28 / 16 | 36M | 26M |
| Q3 2024 | 120 | 160M | 49.1% | 32 / 45 | 16 / 18 | 28M | 17M |
| Q2 2024 | 107 | 161M | 49.4% | 36 / 28 | 22 / 38 | 35M | 24M |
| Q1 2024 | 109 | 151M | 46.2% | 36 / 29 | 27 / 14 | 46M | 26M |
| Q4 2023 | 87 | 130M | 40.0% | 32 / 30 | 11 / 8 | 24M | 24M |
| Q3 2023 | 63 | 130M | 39.9% | 35 / 14 | 6 / 11 | 120M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TSHA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 9,138,043 | 2.80% | $62.23M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,245,134 | 1.92% | $42.53M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,565,638 | 1.71% | $37.90M | 0.35% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 4,176,103 | 1.28% | $24.51M | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 3,044,554 | 0.93% | $20.73M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,622,724 | 0.80% | $15.37M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,213,229 | 0.68% | $15.07M | 0.10% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,687,467 | 0.52% | $11.49M | 0.13% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,147,608 | 0.35% | $6.74M | 0.02% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,134,540 | 0.35% | $6.66M | 0.04% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 1,098,103 | 0.34% | $6.45M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,069,955 | 0.33% | $6.28M | 0.03% | May 31, 2026 |
| Select Biotechnology Portfolio | 940,476 | 0.29% | $5.52M | 0.10% | May 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 810,815 | 0.25% | $5.52M | 0.10% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 759,920 | 0.23% | $4.46M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sukumar Nagendran | President and Head of R&D, Director | 936,410 | 0.29% | Jul 10, 2026 |
| Sean P. Nolan | Chief Executive Officer, Director | 4,443,802 | 1.36% | Jan 27, 2026 |
| Kamran Alam | CHIEF FINANCIAL OFFICER | 1,442,131 | 0.44% | Feb 6, 2026 |
| Laura Sepp-Lorenzino | Director | 127,178 | 0.04% | Jun 2, 2026 |
| Alison S. Long | Director | 127,178 | 0.04% | Jun 2, 2026 |
| Phillip B. Donenberg | Director | 241,289 | 0.07% | Jun 2, 2026 |
| John A. Stalfort III | Director | 2,060,849 | 0.63% | Jun 2, 2026 |
| Paul B. Manning | 10% owner | 4,175,037 | 1.28% | Jun 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sukumar Nagendran President and Head of R&D, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −200,000 | $6.24 | $1.25M | 936,410 |
| Phillip B. Donenberg Director | Jun 1, 2026 | Award | +21,335 | – | – | 241,289 |
| John A. Stalfort III Director | Jun 1, 2026 | Award | +21,335 | – | – | 1,176,559 |
| Laura Sepp-Lorenzino Director | Jun 1, 2026 | Award | +21,335 | – | – | 127,178 |
| Alison S. Long Director | Jun 1, 2026 | Award | +21,335 | – | – | 127,178 |
| Sukumar Nagendran President and Head of R&D, Director | Apr 10, 2026 | Option exercise | +19,021 | $1.71 | $32.53K | 1,336,410 |
| Sukumar Nagendran President and Head of R&D, Director | Apr 10, 2026 | Sale(10b5-1 plan) | −200,000 | $4.46 | $892.00K | 1,136,410 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Feb 4, 2026 | Sale | −1,655 | $4.52 | $7.48K | 1,442,131 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Jan 26, 2026 | Sale | −23,849 | $4.61 | $109.94K | 1,443,786 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 26, 2026 | Sale | −41,312 | $4.61 | $190.45K | 2,908,257 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 26, 2026 | Sale | −26,918 | $4.61 | $124.09K | 1,317,389 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Jan 23, 2026 | Sale | −78,968 | $4.75 | $375.10K | 1,467,635 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 23, 2026 | Sale | −136,789 | $4.75 | $649.75K | 2,949,569 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 23, 2026 | Sale | −89,132 | $4.75 | $423.38K | 1,344,307 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 12, 2026 | Award | +1,008,000 | – | – | 3,086,358 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 12, 2026 | Award | +427,000 | – | – | 1,433,439 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 12, 2026 | Sale(10b5-1 plan) | −200,000 | $4.71 | $942.00K | 1,006,439 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 12, 2026 | Option exercise | +111,324 | $0.70 | $77.93K | 1,117,763 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 12, 2026 | Option exercise | +88,676 | $1.71 | $151.64K | 1,206,439 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Jan 12, 2026 | Award | +359,000 | – | – | 1,546,603 |
| Sukumar Nagendran President and Head of R&D, Director | Dec 1, 2025 | Option exercise | +260,047 | $1.71 | $444.68K | 1,266,486 |
| Sukumar Nagendran President and Head of R&D, Director | Dec 1, 2025 | Sale | −260,047 | $4.51 | $1.17M | 1,006,439 |
| Sukumar Nagendran President and Head of R&D, Director | Nov 28, 2025 | Option exercise | +70,172 | $0.70 | $49.12K | 1,076,611 |
| Sukumar Nagendran President and Head of R&D, Director | Nov 28, 2025 | Option exercise | +39,953 | $1.71 | $68.32K | 1,116,564 |
| Sukumar Nagendran President and Head of R&D, Director | Nov 28, 2025 | Sale | −110,125 | $4.75 | $523.09K | 1,006,439 |
| Sukumar Nagendran President and Head of R&D, Director | Sep 10, 2025 | Sale(10b5-1 plan) | −200,000 | $3.23 | $646.00K | 1,006,439 |
| Sukumar Nagendran President and Head of R&D, Director | Sep 10, 2025 | Option exercise | +41,150 | $0.70 | $28.80K | 1,206,439 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Aug 21, 2025 | Sale | −54,491 | $2.85 | $155.30K | 1,187,603 |
| Sukumar Nagendran President and Head of R&D, Director | Aug 21, 2025 | Sale | −57,054 | $2.85 | $162.60K | 1,165,289 |
| Laura Sepp-Lorenzino Director | Jun 2, 2025 | Award | +56,623 | – | – | 105,843 |
| Alison S. Long Director | Jun 2, 2025 | Award | +56,623 | – | – | 105,843 |
| Phillip B. Donenberg Director | Jun 2, 2025 | Award | +56,623 | – | – | 219,954 |
| John A. Stalfort III Director | Jun 2, 2025 | Award | +56,623 | – | – | 1,155,224 |
| Paul B. Manning 10% owner | May 30, 2025 | Buy | +750,000 | $2.75 | $2.06M | 2,841,704 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Mar 11, 2025 | Tax withholding | −29,843 | $1.69 | $50.43K | 1,242,094 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 2, 2025 | Award | +324,500 | – | – | 1,222,343 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Jan 2, 2025 | Award | +431,000 | – | – | 1,271,937 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 2, 2025 | Award | +892,500 | – | – | 2,078,358 |
| Paul B. Manning 10% owner | Jun 27, 2024 | Buy | +1,333,333 | $2.25 | $3.00M | 1,333,333 |
| Alison S. Long Director | May 29, 2024 | Award | +49,220 | – | – | 49,220 |
| Phillip B. Donenberg Director | May 29, 2024 | Award | +49,220 | – | – | 163,331 |
| Laura Sepp-Lorenzino Director | May 29, 2024 | Award | +49,220 | – | – | 49,220 |
| John A. Stalfort III Director | May 29, 2024 | Award | +49,220 | – | – | 1,098,601 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Feb 2, 2024 | Tax withholding | −1,288 | $1.51 | $1.94K | 840,937 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 2, 2024 | Award | +863,617 | – | – | 897,843 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 2, 2024 | Award | +1,184,688 | – | – | 1,185,858 |
| Kamran Alam Chief Financial Officer | Jan 2, 2024 | Award | +590,413 | – | – | 842,225 |
| Paul B. Manning 10% owner | Nov 17, 2023 | Buy | +100,000 | $1.63 | $163.00K | 16,566,667 |
| Kamran Alam Chief Financial Officer | Aug 24, 2023 | Sale(10b5-1 plan) | −33,000 | $2.33 | $76.89K | 258,042 |
| Sean P. Nolan Chief Executive Officer, Director | Aug 16, 2023 | Buy | +444,444 | $0.90 | $400.00K | 1,535,545 |
| Paul B. Manning 10% owner | Aug 16, 2023 | Buy | +16,466,667 | $0.90 | $14.82M | 16,466,667 |
| John A. Stalfort III Director | Aug 16, 2023 | Gift | +50,000 | – | – | 1,049,381 |
| John A. Stalfort III Director | Aug 16, 2023 | Buy | +388,889 | $0.90 | $350.00K | 999,381 |
| John A. Stalfort III Director | Aug 16, 2023 | Buy | +388,889 | $0.90 | $350.00K | 884,290 |
| Phillip B. Donenberg Director | Aug 16, 2023 | Buy | +111,111 | $0.90 | $100.00K | 114,111 |
| R.A. Session II 10% owner | Jul 13, 2023 | Sale | −5,344 | $0.70 | $3.74K | 8,871,747 |
| R.A. Session II 10% owner | Jul 12, 2023 | Sale | −80,528 | $0.71 | $57.17K | 8,877,091 |
| R.A. Session II 10% owner | Jun 23, 2023 | Sale | −18,100 | $0.70 | $12.67K | 8,957,619 |
| R.A. Session II 10% owner | Jun 22, 2023 | Sale | −10,508 | $0.70 | $7.36K | 8,975,719 |
| R.A. Session II 10% owner | Jun 21, 2023 | Sale | −138,962 | $0.70 | $97.27K | 8,986,227 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sukumar Nagendran Officer | Jul 10, 2026 | 200,000 | $1.30M | Jul 10, 2026 | Stock Option Grant |
| Sukumar Nagendran Officer | Apr 10, 2026 | 200,000 | $926.00K | Apr 10, 2026 | RSU Grant |
| Haque-Ahmed Rumana Officer | Feb 27, 2026 | 2,405 | $10.99K | Feb 27, 2026 | RSU Award |
| Alam Kamran Officer | Feb 4, 2026 | 1,655 | $7.81K | Feb 4, 2026 | RSU Award |
| Haque-Ahmed Rumana Officer | Feb 4, 2026 | 697 | $3.29K | Feb 4, 2026 | RSU Award |
| McAuliffe Sean Affiliate - Chief Business Officer | Feb 4, 2026 | 914 | $4.31K | Feb 4, 2026 | RSU Award |
| Porter Fred Affiliate-Chief of Staff & Tech.Op.Officer | Feb 4, 2026 | 889 | $4.20K | Feb 4, 2026 | RSU Award |
| McGinnis Emily Affiliate-Chief Pat. Adv. & Ext. Aff. Off. | Feb 4, 2026 | 901 | $4.25K | Feb 4, 2026 | RSU Award |
| Alam Kamran Officer | Jan 23, 2026 | 100,846 | $513.31K | Jan 23, 2026 | RSU Award |
| McAuliffe Sean Affiliate - Chief Business Officer | Jan 23, 2026 | 46,064 | $234.47K | Jan 23, 2026 | RSU Award |
| McGinnis Emily Affiliate-Chief Pat. Adv. & Ext. Aff. Off. | Jan 23, 2026 | 32,077 | $163.27K | Jan 23, 2026 | RSU Award |
| Haque-Ahmed Rumana Officer | Jan 23, 2026 | 30,052 | $152.96K | Jan 23, 2026 | RSU Award |
| Nagendran Sukumar Officer | Jan 23, 2026 | 113,824 | $579.36K | Jan 23, 2026 | RSU Award |
| P. Nolan Sean Officer, Director | Jan 23, 2026 | 168,078 | $855.52K | Jan 23, 2026 | RSU Award |
| Porter Fred Affiliate-Chief of Staff & Tech.Op.Officer | Jan 23, 2026 | 54,916 | $279.52K | Jan 23, 2026 | RSU Award |